A new report commissioned by NHS England (NHSE): Evaluating Pathways for AI Dermatology in Skin Cancer Detection states Skin Analytics’ Artificial Intelligence as a Medical Device (AIaMD), DERM, can be used autonomously in the NHS.
We were delighted to see research into the publicly available skin cancer datasets many use to train AI systems to assess skin cancer published in The Lancet Digital Health last week.
Applying academic rigour to a long known issue around machine learning helps to educate the industry around one of the foundations on which AI systems are built; training data.
In this blog as Medical Director of Skin Analytics, I wanted to share with the wider dermatology community our position regarding our regulatory status and why you can safely deploy our medical device DERM.
In February 2020, skin cancer researchers released a paper calling into question…
The prospective, diagnostic trial saw DERM, our AI platform, correctly identify all malignant lesions (100% sensitivity) with an average AUROC of 95.8% with 65% specificity versus 70% specificity and a 77% AUROC score demonstrated by the clinical experts. DERM, a CE marked medical device, was developed as a tool to aid clinicians in identifying 11 common skin lesion types, including melanoma.
The University of Heidelberg has published a paper in the Annals of Oncology that demonstrates the important role that artificial intelligence (AI) can play in melanoma detection.
QIMR Berghofer has released an online test that helps to identify whether you are at a high risk of developing melanoma within the next 3 and a half years.
